Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study

Abstract

Summary:Healthy allogeneic donors, who were treated with G-CSF and underwent peripheral blood haematopoietic precursor collection at our Institution, were enrolled in a short-and long-term haematological surveillance protocol for a 5-7-year period. To date, 94 donors have been assessed with a mean follow-up of 30 months (4-84); for 30 subjects, the follow-up is X48 months. During G-CSF administration, 23/94 donors showed a significant platelet count decrease from the baseline. Pre-apheresis platelet decrement correlated with the total G-CSF dose administered, baseline platelet level and donor age. Normal platelet counts returned within 4-8 months. PMN and/or lymphocyte lower values were observed in 55/94 donors 2 weeks after G-CSF administration, with mean drops from the baseline of 40 and 36% for PMN and lymphocytes, respectively. The PMN decrease correlated inversely with donor age, as younger donors were more affected than older ones, whereas the lymphocyte decrease correlated directly with the total blood volumes processed in the apheresis courses, in particular for donors subjected to large volume leukaphereses. Long-term observation showed moderate neutrophil reduction (25% count drop from the baseline) in four of the 30 donors observed for four years or more. 14 donors showed persistent, slight lymphocytopenia (mean drop of 13%) until the third year, with recovery in the fourth year of follow-up.

Allogeneic peripheral blood stem cell collection as of 2008

“…As reported by Tassi et al [25], filgrastim also causes a mild-to-moderate decrease in platelet count from baseline in approximately 25% of healthy allogeneic donors. Platelet counts returned to normal within 4 to 8 months.…”

Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study

“…16,17,19,29 We recorded an almost negligible Table 2b Reported events and health impairment in PBPC donors o 50 years of age (n ¼ 56) and X50 years of age (n ¼ 38)…”

“…Our observations concerning the post-donation course of peripheral blood and differential counts were in line with earlier reports. [16][17][18][19] Day 100 of follow-up revealed normal WBC counts in nearly all evaluable donors (median 5.9 g/l, range 3-8.8). At this time, the relative lymphocyte count was normal in the investigated subjects (data not shown).…”

“…The laboratory results of our donors during the early post-donation course regarding WBC and platelet counts were in line with earlier reports. 1,[16][17][18][19]29 Our questionnaire included the history of intercurrent diseases, surgical interventions and the need for new medications in the post-donation period. Most events occurred in donors who were 50 years of age and older at the time of query.…”

Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

“…Smaller studies from related donors suggest that these frequent side effects occur with the same pattern in related donors. [12][13][14][15] Sporadic case reports and a recent large survey among transplant teams demonstrate that the donation procedure can be associated with a small but real risk for serious adverse events and reactions (SAE/R). [16][17][18][19] Current experience suggests that risks seem to be higher for related than for unrelated donors with the caveat of reporting bias and lack of an adequate amount of prospective follow-up data in the related donor setting.…”